Please assess the completion status of the following clinical trial:

Trial Title: Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male, between 30 and 50 years~* HIV-1 RNA \< 50 copies/mL on screening visit~* on Atripla continuously for ≥6 months preceding the screening visit~* Have a HIV genotype prior to starting cART with Atripla with no known resistance to any of the study agents at any time in the past including, but not limited to RT mutations K65R, K101E/P, E138G/K/Q/R, Y181C/I/V, M184V/I and H221Y~* Negative TPHA or VDRL \< 12 months prior to the screening visit~* no signs of an acute or chronic hepatitis C infection within the past 12 months before screening as defined in the Dutch guideline (Arends et al. Neth J Med 2011)~* No subjective neurocognitive complaints in the preceding 12 months~* willingness to take Eviplera together with food according to the manufacturer's prescriptions.~* Estimated glomerular filtration rate ≥50 mL/min (Cockcroft-Gault formula) on last routine measurement during outpatient clinic~* able to understand and comply to study procedures and to provide written informed consent~Exclusion Criteria:~* Non-native Dutch speakers~* Proven major depression through psychiatric consultation within the past year or on anti-depressant drugs (SSRI or TCA)~* Active or known from medical history past CNS opportunistic infections~* History of proven neurologic disease (e.g. multiple sclerosis, brain tumor, cerebrovascular event, etc)~* Active psychiatric disorders classified according to the DMS V criteria~* History or evidence of alcohol or drug abuse defined according to DSM V criteria~* TSH within normal reference values on last routine measurement during outpatient clinic~* Contraindications for undergoing an MRI; a pacemaker or metallic devices/foreign bodies in situ, proven claustrophobia.

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): patients switching from Atripla to Eviplera
- Control (Type: NO_INTERVENTION): patients remaining on Atripla

Based on this trial design, predict the completion outcome and termination type (if applicable).